| Literature DB >> 29751611 |
Gavin Hackett1, Kevin Moore2, David Burgin3, Fraser Hornby4, Bryony Gray5, Mark Elliott6, Imran Mir7, Matthew Beard8.
Abstract
We have purified and characterized recombinant botulinum neurotoxin serotype FA (BoNT/FA). This protein has also been named as a new serotype (serotype H), but the classification has been controversial. A lack of well-characterized, highly pure material has been a roadblock to study. Here we report purification and characterization of enzymatically active, and of inactive nontoxic, recombinant forms of BoNT/FA as tractable alternatives to purifying this neurotoxin from native Clostridium botulinum. BoNT/FA cleaves the same intracellular target proteins as BoNT/F1 and other F serotype BoNTs; the intracellular targets are vesicle associated membrane proteins (VAMP) 1, 2 and 3. BoNT/FA cleaves the same site in VAMP-2 as BoNT/F5, which is different from the cleavage site of other F serotype BoNTs. BoNT/FA has slower enzyme kinetics than BoNT/F1 in a cell-free protease assay and is less potent at inhibiting ex vivo nerve-stimulated skeletal muscle contraction. In contrast, BoNT/FA is more potent at inhibiting neurotransmitter release from cultured neurons.Entities:
Keywords: SNARE proteins; bacterial toxin; botulinum toxin; neurotoxin; neurotransmitter release; protein purification; proteolytic enzyme; recombinant protein expression
Mesh:
Substances:
Year: 2018 PMID: 29751611 PMCID: PMC5983251 DOI: 10.3390/toxins10050195
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546